CSI Market
Sign In | Register

Cocrystal Pharma Inc (COCP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access COCP Annual Cash Flow →
Looking at cash flow data from Cocrystal Pharma Inc through Jun 30 2025 provides insight into Jun 30 2026's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-5.46
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.18
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.05
Deferred Other Tax Expense Benefit-
Stock Issued-
Accounts Payable And Accrued Expenses One-
Liabilities Assumed-
Fair Value Of Series Preferred Stock Issued In Acquisition Of Rfs Pharma Llc-
Fair Value Of Stock Options Issued In Acquisition Of Rfs Pharma Llc-
Derivative Gain Loss On Derivative Net-
Deferred Income Tax-
Interest Expense-
Finance Lease Right Of Use Asset Amortization-
Operating Lease Expense-
Increase Decrease In Value Added Tax Receivable-
Operating Lease Right Of Use Asset Amortization Expense0.08
Increase Decrease In Grant Receivable-0.07
Increase Decrease In Operating Lease Liability-0.08
Income taxes0.00
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Increase (Decrease) in Income Taxes Receivable0.03
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.39
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.05
Other Working Capital-0.16
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.16
Discontinued operations0.00
Net Cash flow from Operating Activities-4.86
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Acquired In Acquisition Of Rfs Pharma Inc.-
Principal Payments Received On Mortgage Note Receivable-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale and Collection of Mortgage Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net0.00
Borrowings From Noteholders-
Payment To Shareholders-
Proceeds From Sale Of Preferred Shares-
Proceeds From Issuance Of Common Stock-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-4.86
Total Cash Flow-4.86
4 historic quarters locked

Sign in to unlock the full Cocrystal Pharma Inc cash flow history.

Sign In Create Free Account

About Cocrystal Pharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037573

Figures are derived from filed reports and may be restated. Historical data is subject to revision.